IL3RA is an inclusion criterion in 14 clinical trials for acute myeloid leukemia, of which 12 are open and 2 are closed. Of the trials that contain IL3RA status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (2 open), 9 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

IL3RA is an inclusion criterion in 8 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 7 are open and 1 is closed. Of the trials that contain IL3RA status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [4].

IL3RA is an inclusion criterion in 4 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 1 is closed. Of the trials that contain IL3RA status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

IL3RA is an inclusion criterion in 4 clinical trials for B-cell acute lymphoblastic leukemia, of which 4 are open and 0 are closed. Of the trials that contain IL3RA status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (3 open) [4].

IL3RA is an inclusion criterion in 2 clinical trials for chronic myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain IL3RA status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

IL3RA is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 1 is open and 1 is closed. Of the trials that contain IL3RA status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].

IL3RA is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain IL3RA status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and myeloid neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for refractory hematologic malignancy, of which 0 are open and 1 is closed. Of the trial that contains IL3RA status and refractory hematologic malignancy as inclusion criteria, 1 is phase 2 (0 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for systemic mastocytosis, of which 0 are open and 1 is closed. Of the trial that contains IL3RA status and systemic mastocytosis as inclusion criteria, 1 is phase 2 (0 open) [4].

IL3RA is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IL3RA status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].